Medpace (MEDP)
NASDAQHealth CareMedical - Diagnostics & ResearchSnapshot 2026-10-29
$652.01-3.77%
Close 2026-10-30 · 1-day change
NASDAQHealth CareMedical - Diagnostics & ResearchSnapshot 2026-10-29
Research Workspace
Put MEDP beside peers and holdings, graph the same metric, and keep your notes with the evidence.
Daily closes. Earnings/event dots are placed inline.
Industries move in repeating boom-and-bust cycles. This shows where this stock’s industry sits in that cycle, stage by stage (recovery → expansion → supercycle → steady → deceleration → contraction), from its fundamentals (orders, revenue, capital spending), not the stock’s price.
A booming industry is a tailwind for the names in it; a contracting one is a headwind. Companies in the same industry tend to rise and fall together with the cycle, the way a tide lifts and lowers every boat in the harbor at once, so a large part of a stock’s swing can come from where its industry sits rather than from the company itself. It’s context for reading the company’s results, not a buy/sell call. Full explanation →
Life Sciences Tools & Services: structurally weak cohort (structural / late-cycle), so the cyclical early-warning is suppressed.
The stage band shows the industry’s cycle over the chart’s timeline (each color a stage); a ▼ marks a quarter its growth inflected down — amber is an unconfirmed watch, red is confirmed the next quarter. Use “Overlay cycle on chart” to tint the price chart by stage. The industry’s fundamentals, not a signal on this stock.
The reason to own it still holds.
View ThesisRevenue growth is accelerating — up about 20% over the past year.
View GrowthRanks among the strongest in its industry on quality — around the top 11%.
View QualityManagement screens strong on capital allocation, earnings delivery, margins.
View ManagementExpectations look reasonable — what the market is pricing in sits in line with or below what analysts forecast.
View ValuationThis stock is volatile — it swings about 1% on a typical day and fell roughly 37% in its worst 12-month stretch.
View RiskMedpace’s clinical development services must sustain strong growth, though revenue growth has slowed recently. Revenue growth eased from 26.5% to 17.2%, then 8.5%; Q3 earnings still beat consensus. The shares trade at 38× P/E versus 37× for peers and 35× historically. Expectations look modest versus our view, despite the recent growth slowdown. The specific risk is slower revenue growth and weaker backlog conversion. Our model puts the next-quarter miss probability near 18%. Peer multiples imply a price about 11% below where it trades; our read remains intact. This read is provisional.
Trailing returns as of 2026-10-30. MEDP is total return (includes dividends); the S&P 500 benchmark is price return (the index excludes dividends).
Based on 14 analysts currently covering MEDP (as of Oct 2026).
Based on 10 Wall Street analysts offering 12-month price targets for MEDP in the last 4 months.
Continue this research
Compare MEDP with peers and holdings, graph the same reported metric, keep your questions beside the evidence, and return when the facts change.
Compare now without an account. Saving and monitoring require an account.
| Compare | Company | Living FV | P/E | Revenue % | Quality |
|---|---|---|---|---|---|
| MEDP Selected company | Graph | Compare | Trend | Review | |
| Peer Add a competitor | Graph | Compare | Trend | Review | |
| Holding Compare a holding | Graph | Compare | Trend | Review |
Selected metric trend
Quarterly · checked companies · value or % of revenue
A consensus fair price across 11 valuation methods, at three horizons. As of 2026-10-30. Estimates are diagnostics, not price targets. Short-horizon estimates are close to coin-flips, so confidence is a method-agreement read, not a prediction.
Today's peer multiple on trailing earnings, with no growth credited. This is the headline read.
Adds projected growth, so it leans optimistic by design. Read it as upside context, not a base case.
A price-focused, side-by-side fair-value read versus Life Sciences Tools & Services — fair value, gap to price, and forward P/E.
Compare the value case
Put MEDP next to peers and holdings, compare Living FV and multiples, then graph the driver behind the difference.
Threatens: Increase revenue growth
Lower revenue-growth guidance and backlog conversion signal a meaningful near-term growth headwind.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
End-of-day figures as of 2026-10-30. EPS is implied from price ÷ P/E. Not investment advice.
Current $652.01
The last 12 months of price, then the range of analyst 12-month targets from today’s $652.01.
Analyst ratings and price targets are third-party Wall Street estimates, not QuarterlyIQ’s view. Not investment advice.
A long-thesis check that carries the widest uncertainty of the three horizons.
Top 10% on quality vs scored peers
A second lens on the 12-month fair value: for companies that score high on measured quality (profitability, balance-sheet safety, earnings stability), this read trusts more of today's profit margins instead of averaging them toward their multi-year history the way the headline number does. Shown alongside the fair value above, not in place of it. A diagnostic, not a price target or a buy/sell signal.
Direction of the business behind the multiple. Bands are backend reads; trailing-12-month basis.
Advances: Continue the share repurchase program
New $1B authorization supports repurchases; 2026 EPS forecast provides earnings outlook.
Advances: Grow revenue through clinical development services
Record awards, a profit beat, and raised guidance materially strengthen growth and earnings outlook.
Earnings and revenue beat estimates, supporting growth and profitability objectives.
Advances: Increase revenue growth
Raising guidance indicates strong revenue growth potential.
Advances: Increase revenue growth
Solid earnings indicate revenue growth improvements.
